India Healthcare Contract Development and Manufacturing Organization Market Trends, Sales Performance, Procedure Volume, Healthcare Spending, Technology Adoption, Reimbursement Analysis, Competitive Landscape, and Growth Outlook

Revenue, 2025

USD 12.07 Bn

Forecast Year, 2035

USD 34.89 Bn

CAGR, 2026 - 2035

8.39%

Report Coverage

India

The India healthcare contract development and manufacturing organization market size was evaluated at USD 12.07 billion in 2025 and is expected to grow around USD 34.89 billion by 2035, registering a CAGR of 8.39% from 2026 to 2035. The market is mainly driven by cost benefits, a large pool of skilled scientific professionals, the need for global supply chain diversification from China, and strong government support through initiatives like the Production-Linked Incentive (PLI) schemes.

India Healthcare Contract Development and Manufacturing Organization Market Statical Scope

The Indian Healthcare Contract Development and Manufacturing Organization (CDMO) market is crucial as it offers global pharmaceutical companies affordable and large-scale drug production. With a vast pool of scientific talent, advanced regulatory compliance, and unmatched expertise in generic manufacturing, India advances global drug delivery and reinforces its role as the "Pharmacy of the World." The country has significantly lower labor and operational costs compared to Western markets, along with a large English-speaking workforce of scientists, engineers, and technical experts.

There is also a high number of US FDA-approved manufacturing facilities that meet global quality standards. The robust infrastructure can manage large volumes of generic drugs and complex biologics. Global pharmaceutical companies are increasingly relying on Indian CDMOs to cut capital costs and accelerate their time-to-market. There is rapid growth in the development of large molecules and biosimilars to meet the needs of modern medicine. Regional hubs like Hyderabad's Pharma City offer localized, comprehensive supply chain ecosystems.

India Healthcare Contract Development and Manufacturing Organization Market, By Services, 2025 (%)

• Contract Manufacturing - The contract manufacturing sector, with a share of 62% in 2025, accounts for the largest revenue share in India's healthcare CDMO market due to affordable production, advanced technical skills, and significant scaling capabilities. This allows both global and local companies to reduce costs while adhering to stringent international quality standards for generics, complex injectables, and biologics.
• Contract Development - The contract development sector, with a share of 38% in 2025, is crucial in India's CDMO market as it provides important early-stage scientific knowledge, process improvement, and intricate formulation design. This helps global pharmaceutical companies to reduce R&D expenses, manage strict regulatory challenges, and smoothly move new molecules and biologics from laboratory scale to commercial production.

Competitive Landscape

The India Healthcare Contract Development and Manufacturing Organization (CDMO) / Contract Manufacturing Organization (CMO) market is driven by cost savings, a talented scientific workforce, and Production-Linked Incentive (PLI) programs. Key players in this sector include Divi's Laboratories, Syngene International, Piramal Pharma Solutions, and Dr. Reddy's Laboratories.

• Divi's Laboratories Limited is A global leader in active pharmaceutical ingredients (APIs), custom synthesis, and advanced intermediates for major pharmaceutical companies.
• Syngene International Limited Provides integrated discovery, development, and manufacturing services for small molecules and biologics, with dedicated R&D facilities.
• Piramal Pharma Solutions offers comprehensive contract development and manufacturing services, with specialized expertise in potent compounds (HPAPIs), sterile injectables, and solid oral dosage forms.
• Dr. Reddy's Laboratories (Custom Pharmaceutical Services) features a portfolio that includes complex generic formulations, unique dosage designs, and large-scale API contract manufacturing.
• Sun Pharmaceutical Industries Limited engages in large-scale commercial manufacturing across various complex therapeutic delivery systems, sterile products, and global generics.
• Aurobindo Pharma Limited & Zydus Lifesciences provide extensive infrastructure for high-volume API synthesis, oral solids, topicals, and emerging biosimilar pipelines.
• Akums Drugs & Pharmaceuticals Limited is A leading domestic contract manufacturer that focuses on a variety of finished formulations, including tablets, capsules, and injectables for numerous domestic and international brands.

Segments Covered in the Report

By Services

• Contract Manufacturing
• Contract Development